GB2305606A - Drug delivery composition for the nasal administration of antiviral agents - Google Patents

Drug delivery composition for the nasal administration of antiviral agents

Info

Publication number
GB2305606A
GB2305606A GB9700817A GB9700817A GB2305606A GB 2305606 A GB2305606 A GB 2305606A GB 9700817 A GB9700817 A GB 9700817A GB 9700817 A GB9700817 A GB 9700817A GB 2305606 A GB2305606 A GB 2305606A
Authority
GB
United Kingdom
Prior art keywords
drug delivery
nasal administration
delivery composition
antiviral agents
bioadhesive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB9700817A
Other versions
GB2305606B (en
GB9700817D0 (en
Inventor
Peter Watts
Lisbeth Illum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Services Ltd
Original Assignee
Danbiosyst UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Danbiosyst UK Ltd filed Critical Danbiosyst UK Ltd
Publication of GB9700817D0 publication Critical patent/GB9700817D0/en
Publication of GB2305606A publication Critical patent/GB2305606A/en
Application granted granted Critical
Publication of GB2305606B publication Critical patent/GB2305606B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Abstract

A drug delivery composition for nasal administration is provided which comprises the antiviral agent ICAM-1 and a bioadhesive material. The bioadhesive material may be a chitosan solution, a liquid formulation comprising a polymeric material or a plurality of bioadhesive microspheres. The polymeric material is preferably gellan gum or alginate. The microspheres may comprise starch, chitosan, hyaluronic acid, or gelatin.
GB9700817A 1994-07-26 1995-07-24 Drug delivery composition for the nasal administration of ICAM-1 Expired - Fee Related GB2305606B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9414966A GB9414966D0 (en) 1994-07-26 1994-07-26 Pharmaceutical compositions for the nasal administration of antiviral agents
PCT/GB1995/001735 WO1996003142A1 (en) 1994-07-26 1995-07-24 Drug delivery composition for the nasal administration of antiviral agents

Publications (3)

Publication Number Publication Date
GB9700817D0 GB9700817D0 (en) 1997-03-05
GB2305606A true GB2305606A (en) 1997-04-16
GB2305606B GB2305606B (en) 1998-08-05

Family

ID=10758832

Family Applications (2)

Application Number Title Priority Date Filing Date
GB9414966A Pending GB9414966D0 (en) 1994-07-26 1994-07-26 Pharmaceutical compositions for the nasal administration of antiviral agents
GB9700817A Expired - Fee Related GB2305606B (en) 1994-07-26 1995-07-24 Drug delivery composition for the nasal administration of ICAM-1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GB9414966A Pending GB9414966D0 (en) 1994-07-26 1994-07-26 Pharmaceutical compositions for the nasal administration of antiviral agents

Country Status (7)

Country Link
EP (1) EP0773791A1 (en)
JP (1) JPH10506376A (en)
CA (1) CA2195639A1 (en)
FI (1) FI970331A0 (en)
GB (2) GB9414966D0 (en)
NO (1) NO970252D0 (en)
WO (1) WO1996003142A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5879712A (en) 1995-06-07 1999-03-09 Sri International Method for producing drug-loaded microparticles and an ICAM-1 dosage form so produced
DE69722594T2 (en) * 1996-03-06 2004-04-29 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield POWDERED MEDICINAL PRODUCT CONTAINING INTERCELLULAR ADHESIVE MOLECULE
GB9700624D0 (en) 1997-01-14 1997-03-05 Danbiosyst Uk Drug delivery composition
GB9707934D0 (en) * 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
AU747211B2 (en) * 1997-07-18 2002-05-09 Bayer Corporation Methods of removing residual solvent from nasal drug delivery compositions
EP1027072A1 (en) * 1997-10-31 2000-08-16 Monsanto Company Controlled release compositions comprising gellan gum gels
DE69831421T2 (en) * 1997-12-02 2006-06-22 Archimedes Development Ltd. COMPOSITIONS FOR NASAL ADMINISTRATION
GB0015682D0 (en) * 2000-06-28 2000-08-16 Bristol Myers Squibb Co Sprayable wound care composition
GB2378383A (en) * 2001-06-06 2003-02-12 Gursharan Moonga Nasal delivery of pharmaceutical compositions in powder form
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
GB0328186D0 (en) 2003-12-05 2004-01-07 West Pharm Serv Drug Res Ltd Intranasal compositions
GB0403938D0 (en) * 2004-02-21 2004-03-24 West Pharm Serv Drug Res Ltd Chitosan containing solution
JP5502494B2 (en) 2007-01-22 2014-05-28 ターガセプト・インコーポレイテッド Intranasal, buccal, or sublingual administration of a metanicotine analog
DE102008007759B4 (en) 2007-12-04 2009-09-24 Atlantichem Gmbh Agent for preventing discoloration when washing textiles

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0314863A2 (en) * 1987-11-02 1989-05-10 Baylor College Of Medicine Use of ICAM-1 or its functional derivatives for the treatment of non-specific inflammation
EP0362531A1 (en) * 1988-09-01 1990-04-11 Bayer Corporation A human rhinovirus receptor protein that inhibits virus infectivity
WO1990005522A1 (en) * 1988-11-17 1990-05-31 Per Prisell Pharmaceutical preparation
WO1991006282A1 (en) * 1989-11-04 1991-05-16 Danbiosyst Uk Limited Small particle drug compositions
WO1993006842A1 (en) * 1991-10-02 1993-04-15 Boehringer Ingelheim Pharmaceuticals, Inc. Use of intercellular adhesion molecules, and their binding ligands in the treatment of asthma
WO1994000485A1 (en) * 1992-06-22 1994-01-06 Miles Inc. Multimeric forms of human rhinovirus receptor protein
WO1994027576A1 (en) * 1993-05-20 1994-12-08 Danbiosyst Uk Limited Nasal drug delivery composition containing nicotine

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0314863A2 (en) * 1987-11-02 1989-05-10 Baylor College Of Medicine Use of ICAM-1 or its functional derivatives for the treatment of non-specific inflammation
EP0362531A1 (en) * 1988-09-01 1990-04-11 Bayer Corporation A human rhinovirus receptor protein that inhibits virus infectivity
WO1990005522A1 (en) * 1988-11-17 1990-05-31 Per Prisell Pharmaceutical preparation
WO1991006282A1 (en) * 1989-11-04 1991-05-16 Danbiosyst Uk Limited Small particle drug compositions
WO1993006842A1 (en) * 1991-10-02 1993-04-15 Boehringer Ingelheim Pharmaceuticals, Inc. Use of intercellular adhesion molecules, and their binding ligands in the treatment of asthma
WO1994000485A1 (en) * 1992-06-22 1994-01-06 Miles Inc. Multimeric forms of human rhinovirus receptor protein
WO1994027576A1 (en) * 1993-05-20 1994-12-08 Danbiosyst Uk Limited Nasal drug delivery composition containing nicotine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Nature Vol. 344 1990. Marlin S et. al. pages 70-72 *
Trends in Biotechnology Vol. 9(8) 1991. ILLUM L pages 285 & 288 *

Also Published As

Publication number Publication date
EP0773791A1 (en) 1997-05-21
GB2305606B (en) 1998-08-05
NO970252L (en) 1997-01-21
GB9414966D0 (en) 1994-09-14
GB9700817D0 (en) 1997-03-05
NO970252D0 (en) 1997-01-21
WO1996003142A1 (en) 1996-02-08
AU707462B2 (en) 1999-07-08
JPH10506376A (en) 1998-06-23
CA2195639A1 (en) 1996-02-08
AU2988695A (en) 1996-02-22
FI970331A (en) 1997-01-27
FI970331A0 (en) 1997-01-27

Similar Documents

Publication Publication Date Title
GB9700624D0 (en) Drug delivery composition
GB2305606A (en) Drug delivery composition for the nasal administration of antiviral agents
IL109800A (en) Sustained release drug formulation containing a tramadol salt comprising cellulose ether and/or cellulose ester having a viscosity between 3,000 and 150,000 mPas
HU76547A2 (en) Process for producing pharmaceutical compositions containing agent in polymer-matrix and in solid solution form and these medicaments
EG20401A (en) Process for preparing of veterinary composition for the treatment of gastric acid related deseases in animals
AU8933391A (en) Medical drug formulation and delivery system
CA2067228A1 (en) Drug delivery system, method for preparing the same and use thereof
ATE171872T1 (en) MEDICINAL PREPARATIONS FOR NASAL ADMINISTRATION CONTAINING POLAR METABOLISM PRODUCTS OF OPIAT ANALGESICS
KR880000088A (en) Sustained release formulation
IL114193A0 (en) Ophthalmic pharmaceutical compositions
HUT75089A (en) Compositions containing hyaluronic acid or it's derivatives and pharmaceutical active agent
HUP9904174A2 (en) Pharmaceutical composition for transdermic delivery
DE69803940D1 (en) OPHTHALMIC COMPOSITION WITH EXTENDED RELEASE CONTAINING WATER-SOLUBLE MEDICINAL PRODUCTS
ATE245450T1 (en) ADHESIVE MICROBEADS COMPREHENSIVE COMPOSITION FOR MEDICINAL ADMINISTRATION
GR3030732T3 (en) Pharmaceutical compositions including a drug, a cross-linked polymeric substance, an oil, and a surface active agent.
CA2311450A1 (en) Pharmaceutical aerosol compositions
ES2071889T3 (en) ORAL MEDICINAL PRODUCT AND COATING AGENT, CONTAINING A POLYSACCHARIDE THAT DECOMPOSES IN THE COLON.
HUP9801414A2 (en) Liquid aqueous pharmaceutical compositions comprising sodium alginate and potassium bicarbonate
WO1996040074A3 (en) Device for releasing aggregation-stabilized, biologically active agent
CA2136607A1 (en) Pharmaceutical Powder Composition Containing Non-Ionic Cellulose Ether Derivative and a Chitin-Derived Polymer
GB2292887A (en) Drug delivery system
HUP9902681A2 (en) Controlled-release pharmaceutical tablet containing a carrier based on cross-linked amylose and hydroxypropylmethylcellulose
IL113359A (en) Polysaccharide drug delivery matrix and slow release pharmaceutical preparation containing it
ES2164566A1 (en) Cosmetic cationic polysaccharides coated miniature capsule product consists of a matrix of polymer gelling hydrocolloids with amino polysugars incorporating the active ingredients
CA2249637A1 (en) Uniform drug delivery therapy

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20050724